| Dr Merary Adaileene Santiago Hernandez, | |
|
226 Calle Opalo Urb Lomas Verdes, Moca, PR 00676 | |
| (939) 406-3452 | |
| Not Available |
| Full Name | Dr Merary Adaileene Santiago Hernandez |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant - Medical |
| Location | 226 Calle Opalo Urb Lomas Verdes, Moca, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821707308 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | 1170-PA (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Merary Adaileene Santiago Hernandez, 226 Calle Opalo Urb Lomas Verdes, Moca, PR 00676 Ph: (939) 406-3452 | Dr Merary Adaileene Santiago Hernandez, 226 Calle Opalo Urb Lomas Verdes, Moca, PR 00676 Ph: (939) 406-3452 |
News Archive
Sucampo Pharmaceuticals, Inc. today presented results of a phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). These data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session.
Haber, Inc. ("Haber"), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called "EMP Diagnostics Inc." ("EDI"). The business of the new company will focus on the application of Haber's Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
A medication known as argatroban, when combined with another drug already used in the treatment of stroke patients, may help restore the flow of blood through blocked arteries.
› Verified 5 days ago
Jaime J Ramos Hernandez, PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Hc 1 Box 6960, Moca, PR 00676 Phone: 939-319-7254 |